Docket Number:12A-1010305
Inventor:Hsiu-Ming Shih, Wei-Chih Yang
IP Status:US 9,353,422B2、TW I534153
Abstract:
PLZF/RARA derived from chromosomal translocation between the retinoic acid receptor alpha (RARA) and promyelocytic leukemia zinc finger (PLZF) is an oncogenic fusion protein associated with acute promyelocytic leukemia. Currently, no effective therappeutic agent is available for such type of leukemia. We identified USP37 deubiquitinating enzyme in the regulation of PLZF/RARA protein stability, providing a potential therapeutic strategy against this type of leukemia.
Fields of Application:
USP37 is a potential therapeutic target for PLZF/RARA-associated acute promyelocytic leukemia.
Advantages when compared to the existing technologies:
Our finding is the first time to demonstrate that oncogenic fusion protein PLZF/RARA-elicited cell transformation can be regulated by deubiquitinating enzyme USP37.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
